E
Evotec SE (EVO)
NMS – Real vaqt narxi. Valyuta: USD
2.74
+0.03 (1.11%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.74
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
2.74
+0.03 (1.11%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.74
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 4:10 PM EDT
Evotec SE Amerika Qo'shma Shtatlari, Germaniya, Fransiya, Buyuk Britaniya, Shveytsariya va xalqaro miqyosda dori-darmonlarni kashf qilish va rivojlantirish kompaniyasi sifatida faoliyat yuritadi. U ikkita segmentda ishlaydi: Birgalikdagi tadqiqot va ishlanmalar (Shared R&D) va Just – Evotec Biologics. Kompaniya turli terapevtik sohalarda, jumladan, onkologiya, autoimmün kasalliklar, saraton, diabet, yurak etishmovchiligi, immunologiya, og'riq va yallig'lanish, yuqumli, buyrak, jigar, nafas olish, fibrotik va metabolik kasalliklar, shuningdek, kam uchraydigan kasalliklarda farmatsevtika mahsulotlarini ishlab chiqmoqda. Shuningdek, u markaziy asab tizimi (MAS) va kardiyometabolik kasalliklar; hamda hayvonlar va ayollar salomatligi uchun vositalarni ishlab chiqmoqda. Masa Mass General Brigham va Joslin Diabetes Center bilan kardiyometabolik kasalliklarga qaratilgan hamkorlik shartnomalariga ega; BMS antiviral; Novo Nordisk hujayra terapiyasi; Oksford universiteti; Germaniya saraton tadqiqot markazi; Gamburg universiteti kasalxonasi; Toronto universiteti, Garvard va Yell universiteti; Jon Hopkins universiteti; Ospedale San Raffaele (OSR); va Singapur milliy universiteti. Muddatdan tashqari, u LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2 va 65LAB bilan hamkorlik qiladi. Bundan tashqari, kompaniya pharma va biotexnologiya kompaniyalari, akademik muassasalar, bemorlarni qo'llab-quvvatlash guruhlari va venchur kapitalga xizmat ko'rsatadi. Evotec SE Almirall, S.A. bilan, shu jumladan bir qator immunitetli yallig'lanish holatlarini o'z ichiga olgan og'ir teri kasalliklari uchun yangi terapevtik vositalarni ishlab chiqish bo'yicha strategik hamkorlikni yo'lga qo'ygan. Kompaniya ilgari Evotec AG nomi bilan tanilgan va 2019-yil aprel oyida Evotec SE nomini olgan. Evotec SE 1993-yilda tashkil etilgan va uning shtab-kvartirasi Gamburg, Germaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance |
| Dr. Christian Wojczewski Ph.D. | CEO & Chairperson of the Management Board |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board |
| Dr. David Hallet | Executive Vice President |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations |
| Dr. Ingrid Mller | COO & Member of Management Board |
| Dr. Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations |
| Ms. Aurelie Dalbiez | Chief People Officer & Member of Management Board |
| Ms. Claire Hinshelwood | CFO & Member of Management Board |
| Uwe Andag | EVP Head of Metabolic Diseases |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-17 | 6-K | tm2618164d1_6k.htm |
| 2026-05-06 | 6-K | tm2613738d1_6k.htm |
| 2026-04-24 | 6-K | tm2612670d1_6k.htm |
| 2026-04-08 | 6-K | tm2611375d1_6k.htm |
| 2026-04-08 | 20-F | evo-20251231x20f.htm |
| 2026-04-07 | 6-K | tm2611286d1_6k.htm |
| 2026-03-10 | 6-K | tm268431d1_6k.htm |
| 2026-01-16 | 6-K | tm263400d1_6k.htm |
| 2026-01-13 | 6-K | tm263046d1_6k.htm |
| 2026-01-08 | 6-K | tm262587d1_6k.htm |